
AARD
Healthcare · Biotechnology · $29.1M market cap
$1.33-0.19 (-12.5%)Nov 13, 4:18 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +0.9% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | -0.69 | -0.88 | -27.5% |
| Aug 11, 2026 | After the close | -0.87 | -0.66 | +24.1% |
| Apr 6, 2026 | Time not confirmed | -0.80 | -0.99 | -23.8% |
| Mar 23, 2026 | After the close | -0.83 | -0.81 | +2.4% |
| Nov 13, 2025 | After the close | -0.82 | -0.75 | +8.5% |
| Aug 13, 2025 | After the close | -0.60 | -0.66 | -10.0% |
| May 14, 2025 | After the close | -0.61 | -0.71 | -16.4% |
| Mar 31, 2025 | Time not confirmed | -0.20 | -0.43 | -117.5% |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.